Trials / Completed
CompletedNCT05450601
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
A Multicenter, Randomized, Doube-blind, Phase III Study to Evaluate the Efficacy and Safety of HCP2102 in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, phase III study to evaluate the efficacy and safety of HCP2102 in patients with essential hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP2102-1 | Take once daily for 2 weeks orally |
| DRUG | HPP2104-1 | Placebo drug. Take once daily for 2 weeks orally |
| DRUG | HCP2102-2 | Take once daily for 6 weeks orally |
| DRUG | HPP2104-2 | Placebo drug. Take once daily for 6 weeks orally |
| DRUG | RLD2106-1 | Take once daily for 2 weeks orally |
| DRUG | HPP2103-1 | Placebo drug. Take once daily for 2 weeks orally |
| DRUG | RLD2106-2 | Take once daily for 6 weeks orally |
| DRUG | HPP2103-2 | Placebo drug. Take once daily for 6 weeks orally |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2023-12-11
- Completion
- 2023-12-11
- First posted
- 2022-07-11
- Last updated
- 2024-03-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05450601. Inclusion in this directory is not an endorsement.